Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for acute coronary syndrome
IRCT20201117049420N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Sep 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in acute coronary syndrome (ACS) comparing Standard treatment plus placebo with Standard treatment plus colchicine (2 arms). Primary endpoints: All-cause mortality, Stroke and 3 more. Started Sep 2019; status: completed.
02
Drugs
colchicine
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20201117049420N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201117049420N1.